After a year of hard work, LATAM Bif-SOLACI has included over 700 patients! From SOLACI Research and the Registry Board of Directors we are glad to lead this important research initiative and we hope to keep growing in the coming months and be able to contribute with reliable data that will allow us to perfect<a href="https://solaci.org/en/2022/02/14/latam-bif-registry-has-enrolled-over-700-patients/" title="Read more" >...</a>
According to this recent analysis published in Eur Heart J, women would have a far lower chances of dying suddenly for physical exertion during sports compared against men. Women seem to be better protected against this event, which rises the following question: what the value of screening? The risk of sports related sudden death is<a href="https://solaci.org/en/2022/01/06/women-present-lower-risk-of-sport-related-sudden-death-compared-to-men/" title="Read more" >...</a>
This last year, new data in structural heart disease gave way to changes in practices and new hypotheses, when not simply further justified the already existing evidence. In this new editorial section, we share the most relevant of last year’s works to keep you up to speed on the main topics in the field. The<a href="https://solaci.org/en/2022/01/05/the-most-relevant-of-2021-in-structural-heart-disease/" title="Read more" >...</a>
2021 was filled with challenges for SOLACI. Many of the initiatives we started planning in 2020 saw the light and became a reality that strengthens our society’s reach and mission. And not just that: we have also stepped up our efforts to expand and develop our traditional institutional activities always with the intent to add<a href="https://solaci.org/en/2021/12/30/solacis-year/" title="Read more" >...</a>
01- ISCHEMIA: Prognosis is Determined by Anatomy, not Functionality The ISCHEMIA study keeps providing scientific news. This work in patients with stable coronary artery disease had already shown (to our surprise) that ischemic burden does not predict 4-year mortality. Read also HERE 02- Chile Sessions 2021 | Clinical Case Contest for Young Interventionists It is with great<a href="https://solaci.org/en/2021/11/05/the-most-read-articles-in-interventional-cardiology-in-october/" title="Read more" >...</a>
The contest ended. The authors of the selected cases for live presentation have been contacted by email Call for Case Submission XLIII SOLACI Regional Sessions – 14th Southern Cone. Nov 27, 2021 – Chile Sessions. It is with great pleasure that we hereby invite all young Latin American cardiologists to submit relevant clinical cases related<a href="https://solaci.org/en/2021/10/19/solaci-sessions-2021-clinical-case-contest-for-young-interventionists/" title="Read more" >...</a>
According to this large European registry, drug-eluting balloons (DEBs) are competing with drug-eluting stents (DES) to treat in-stent restenosis. Drug-eluting balloons seem to work equally well for the treatment of long-term in-stent restenosis compared with new stent implantation (for the thin-strut DES registry). If DEBs can compete with DES—adding to the advantage of avoiding a<a href="https://solaci.org/en/2021/10/13/drug-eluting-balloons-find-their-niche/" title="Read more" >...</a>
In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and<a href="https://solaci.org/en/2021/09/29/tavr-and-anticoagulation-direct-anticoagulant-agents-or-vitamin-k-inhibitors/" title="Read more" >...</a>
Cardiologists of Lubbock Location: E-mail: rvxsw@suddenlink.net
Early intervention in asymptomatic valvular heart disease, age recommendations to decide between TAVR and surgery for aortic stenosis, and a push in favor of transcatheter repair in secondary mitral regurgitation are some of the new modifications to the European Society of Cardiology (ESC) Guidelines for the Management of Valvular Heart Disease. This new document was<a href="https://solaci.org/en/2021/09/09/esc-2021-updated-european-society-of-cardiology-guidelines-for-the-management-of-valvular-heart-disease/" title="Read more" >...</a>